BC is clinically classified into hormone receptor (HR)-positive, HER2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes based on the expression of estrogen receptors (ER), progesterone receptors (PR), and HER2 receptors. Here, PGR is linked to breast cancer.